Current transcatheter devices to treat functional tricuspid regurgitation with discussion of issues relevant to clinical trial design

Rebecca T. Hahn

Columbia University Medical Center, New York Presbyterian Hospital, New York, NY, USA

Correspondence to: Rebecca T. Hahn, MD, FACC, FASE. Columbia University Medical Center, New York-Presbyterian Hospital, 177 Fort Washington Avenue, New York, NY 10032, USA. Email: rth2@columbia.edu.

Functional or secondary tricuspid regurgitation (TR) has seen increased attention in recent times as relationships with clinically-relevant outcomes have come to light. Despite the association of increased mortality with significant TR, the disease remains under-recognized and thus relatively untreated. In addition, the disease itself has not been extensively studied and the interactions between annular dilatation, right heart disease and pulmonary hypertension are poorly understood. However, the high mortality and recurrence rate with current surgical replacement or repair techniques is well recognised, opening the door to transcatheter therapies for functional TR. The current perspective reviews the rationale for transcatheter solutions, describes some of the current approaches and discusses the ongoing questions of a poorly-studied condition which may limit the design of clinical trials for this disease.

Keywords: Transcatheter tricuspid valve repair; tricuspid regurgitation (TR)

Submitted Feb 26, 2016. Accepted for publication Feb 16, 2017. doi: 10.21037/acs.2017.03.10

View this article at: http://dx.doi.org/10.21037/acs.2017.03.10

Introduction

Functional or secondary tricuspid regurgitation (TR) is believed to be the most common etiology of severe TR in the western world (1,2). The anatomical etiologies of functional or secondary TR have typically included: right ventricular (RV) dilatation, RV or pulmonary hypertension and RV failure (regional or global) (3). The presence of functional TR, either isolated or in combination with left heart disease, is associated with unfavorable natural history (4,5). Current treatment for TR includes the use of optimal medical therapy involving primarily diuretics, or surgery (6). Surgical mortality for isolated tricuspid valve interventions remain higher than for any other single valve surgery (7,8). Combined tricuspid repair at the time of the left-sided disease treatment is recommended in the setting of trans-thoracic echocardiographic tricuspid annular dilatation (>40 mm or >21 mm/m²) (6). Repairing these patients during their initial valve surgery is the only Class I indication for tricuspid intervention, according to the both ACC/AHA and European guidelines (6,9).

However, moderate-to-severe TR is present in 1.6 million US individuals and only a few (<0.5%) within this population currently undergo surgical tricuspid repair or replacement (10). Recognizing the need for early surgical intervention may be difficult for a number of reasons: the underestimation of TR severity under anesthesia (11); the misconception that TR resolves following mitral valve surgery (12,13); the overestimation of surgical risk when concomitant tricuspid valve surgery is performed at the time of mitral valve surgery (14,15); and the under-appreciation of long-term RV function improvement following correction of TR (16,17). Of note, recent studies show that tricuspid valve surgery combined with left heart surgery is not associated with a significant increase in mortality (18), however, re-operative mortality remains high (19).

Transcatheter options for treating patients with significant residual TR following left heart valve interventions has gained importance. In addition, as more left-sided valve disease is treated with transcatheter therapies, the negative impact of TR on survival in these patients (20-22) has under-scored the importance of
developing transcatheter solutions. Although a number of procedures have been developed, ongoing issues which may influence clinical trial design (CTD) for these devices remain, including: defining the severity of TR, understanding the pathophysiology of the disease, determining appropriate indications for intervention and describing relevant clinical outcomes for the disease process.

**Transcatheter approaches to tricuspid regurgitation**

Given advanced echocardiographic imaging techniques allow consistent and accurate real-time imaging of the tricuspid valve (23), transcatheter solutions to TR are now possible with early trials either ongoing or planned.

**MitraClip for tricuspid regurgitation**

A number of authors have recently reported successful treatment of TR with the MitraClip (Abbott Vascular, Abbott Park, Illinois) (Figure 1A) (24-26). Recently, Vismara et al. (27) developed an *ex vivo* porcine model of functional TR to determine the optimal placement of the clip. If a single clip is used, grasping the medial segment (near the tips) of the septal and anterior or septal and posterior leaflets resulted in the greatest increase in forward flow. If a 2-clip procedure is anticipated, then grasping the commissure and medial segments of the septal and anterior leaflets allowed for the best post-procedural outcome, ensuring a complete re-establishment of physiological-like hemodynamics. Formal trials using this device are needed.

**Caval implants**

Patients with severe TR experience symptoms of chronic right heart failure (peripheral edema, ascites, and orthopnea) with congestive hepatopathy, justifying treatment of the upstream effect of severe TR by placing valved stents within the vena cavae. Lauten et al. (28) first reported implantation of two custom-made transcatheter valves into the superior vena cava (SVC) and inferior vena cava (IVC). This resulted in an immediate fall in vena cava pressures, increase in cardiac output, continued improvement in mean caval pressures, improvement in symptoms and normalization of liver function. A similar single-center study, Heterotopic Implantation Of the Edwards-Sapien XT Transcatheter Valve in the Inferior Vena Cava for the Treatment of Severe Tricuspid Regurgitation (HOVER) trial (ClinicalTrials.gov Identifier: NCT02339974) (29), is currently enrolling.

**TriCinch System**

Numerous studies have shown that in function TR, the tricuspid annulus dilates in the septo-to-lateral direction. Knowing this pathoanatomy, investigators of the TriCinch System (4TECH Cardio, Galway, Ireland) have developed a device that tethers the anteroposterior dimension of the annulus in order to improve coaptation. The delivery system allows trans-femoral fixation of a stainless-steel corkscrew into the anteroposterior tricuspid valve annulus, which is connected through a Dacron band to a self-expanding nitinol stent placed in the hepatic region of the IVC. It has been implanted in a limited number of patients with isolated functional TR, however, no published results are available. The Percutaneous Treatment of tricuspid valve Regurgitation With the TriCinch System™ (PREVENT) trial (ClinicalTrials.gov Identifier: NCT02098200) is currently enrolling in French, Italian, and Swiss centers.

**Forma Spacer**

A simpler approach to a large regurgitant orifice would be to place a device in the center of the regurgitant orifice, reducing the orifice and forming a surface against which the leaflet tips can coapt. The Forma Spacer (Edwards Lifesciences, Irvine, CA) device is implanted from a left subclavian vein approach, introducing an anchor attached to a foam-filled spacer device (Figure 1B). The anchor is positioned within the RV wall at the apex and the attached spacer is positioned within the central coaptation of the leaflets using echocardiographic guidance. The early report of seven successful implants in high-risk patients with severe TR with no procedural complications (30) has led to a US early feasibility trial (ClinicalTrials.gov Identifier: NCT02471807) which is currently enrolling.

**Trialign System**

The Trialign System (Mitralign Inc., Tewksbury, Massachusetts) attempts to replicate the results of the modified Kay bicuspidization procedure, which has shown good mid-term (31) and long-term (2) results. Briefly following trans-jugular access, a radiofrequency wire is advanced across the tricuspid annulus from the ventricular side to the right atrium. The ventricular half of a sutured pledget is delivered and cinched (like a venetian blind) in
the subannular region, and the other half of the pledget is extruded and cinched on the atrial surface of the tricuspid annulus. These steps are then repeated so that two pledgeted sutures are positioned at the commissures of the posterior leaflet and the two pledgeted sutures plicated, effectively bicuspidizing the tricuspid valve (Figure 1C).

Since the first-in-human implantation of their device on the tricuspid annulus (32), a number of devices have been implanted on a compassionate-use basis in Europe. The Early Feasibility of the Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS) in patients with Chronic Functional Tricuspid Regurgitation (SCOUT) Trial completed enrollment and reported the 30 day results at Transcatheter Cardiovascular Therapeutics (TCT) 2016, showing a significant reduction in tricuspid annular area as well as tricuspid regurgitant orifice with a significant increase in left ventricular stroke volume. Associated with these changes was a significant reduction in New York Heart Association (NYHA) Class, improvement in Minnesota Living with Heart Failure Questionnaire (MLHFQ) and 6-minute walk test (6MWT). Extension of the trial was granted by the FDA and the trial is still enrolling.

**Cardioband System**

Recent successes and European CE mark approval of the Cardioband System (Valtech Cardio Ltd., Or Yehuda, Israel) for functional mitral regurgitation (FMR) has shown high procedural success with effectiveness in reduction of regurgitation [FMR ≥3+ was reduced from 77.4% to 10.7% at 1 month after the procedure (P<0.001) and 13.6% (P<0.001) at 7 months], and was associated with improvement in heart failure symptoms [NYHA functional class III/IV decreased from 95.5% to 18.2% after 7 months (P<0.001); exercise capacity as assessed by 6MWT increased from 250±107 to 332±118 m (P<0.001)] and demonstrated a favorable safety profile (no peri-procedural deaths) (33). The Cardioband implant is a polyester sleeve with radiopaque markers spaced 8 mm apart. The sleeve covers the delivery system that deploys anchors guided by trans-esophageal imaging.
A contraction wire is pre-mounted on the Cardioband sleeve and contracting the polyester sleeve from one side is accomplished using a dedicated cinching tool. The tool performs cinching and results in a proportional reduction of the distances between the implanted anchors with significant annular remodeling (34). A number of investigators have successfully performed a modification of the procedure for functional TR in this setting, with initial first-in-man data for its Cardioband Tricuspid (TR) system presented at PCR London Valves 2016. These early compassionate-use cases have shown reductions in annular dimensions, regurgitant volume, orifice areas and mean right atrial pressures. The TRI-REPAIR-CE trial is now enrolling in France and Germany.

**Millipede**

Another new device still in early development is the Millipede device (Millipede Inc., Santa Rosa, CA). This device is a complete, adjustable, semi-rigid ring which is attached to the annulus by rotational anchors positioned at defined intervals. The device has a zigzag appearance like the top of a crown, with the anchors at the lowest points and a collar around the hinge-points at the crests. Annular reduction is then accomplished by repositioning the collars further down the crest, effectively reducing the distance between the anchors. Both mitral and tricuspid implants in patients using direct visualization (open surgery) have been performed and were recently presented at PCR London Valves 2016. Early results for the mitral device show both annular reduction, reduction in MR/TR and favorable left ventricular volume reductions, visualized by computed tomography. A trans-septal procedure is currently being developed. In addition to direct reduction in regurgitation with preservation of leaflet architecture, the Millipe device may potentially be used as a docking station for other transcatheter devices such as the balloon-expandable transcatheter valves currently in use for the aortic valve.

**Indirect annuloplasty**

The trans-atrial intra-pericardial tricuspid annuloplasty (TRAIPTA) device is also currently under investigation, with successful implantation in pre-clinical studies (35). This device is formed from a nitinol wire, pre-shaped into a self-expanding loop to encircle the heart from within the pericardial space. Trans-auricular pericardial access is performed by introducing the device into the right atrium via a trans-femoral vein approach, and using the guidewire to puncture the right atrial appendage. The nitinol loop is then opened and positioned to encircle the heart in the atrio-ventricular groove. The suture is tightened to the desired tension using real-time 1.5-T magnetic resonance imaging (MRI) and the right atrial appendage puncture is closed with an atrial septal occluder. In the initial animal study there were significant reductions in annular area, perimeter and increased tricuspid leaflet-coaptation length. Initial trials in humans may be forthcoming.

**Questions about functional tricuspid regurgitation relevant to clinical trial design**

The following discussion introduces a number of questions important to future CTD and highlights areas that need further study.

**How can we reproducibly determine the severity of tricuspid regurgitation?**

Grading of the severity of the TR has been well-described by the American Society of Echocardiography (ASE) (36) and European Association of Echocardiography (EAE) guidelines (37). However, most of the methods used have been poorly-validated resulting in the use of color Doppler visual estimates of severity that have a number of limitations. The use of multiple parameters is frequently required (38). Quantitative assessment of TR with the proximal isovelocity surface area (PISA) method or relative stroke volumes have again not been well studied or validated. The use of three-dimensional (3D) color Doppler, however, shows promise. Velayudhan et al. (39) was one of the first to correlate standard Doppler methods of quantifying severe TR with planimetry of the 3D vena contracta area (VCA): \(>0.75 \text{ cm}^2\) had a sensitivity of 85.2% and specificity of 82.1%. Chen et al. (40) also showed that severe TR by two-dimensional (2D) criteria was associated with a 3D VCA of \(>0.6\pm0.4 \text{ cm}^2\) and non-severe TR by 2D methods with a 3D VCA of \(\leq0.3\pm0.1 \text{ cm}^2\). Many of the studies validating the use of these Doppler parameters have significant limitations, with a lack of a “gold standard” for comparison or support from outcomes data. Future studies are needed to determine the reproducibility, accuracy and prognostic utility of echocardiography or cardiac MRI parameters.

**What are the predictors of progression/persistence of disease following left heart surgery?**

Following isolated mitral valve repair, significant residual
TR is observed in up to 40% of patients (41). In patients undergoing concomitant TR repair at the time of mitral surgery, persistent severe TR is still present in 11% at 3 months, and 17% at 5 years (42). Predictors for residual regurgitation after surgical repair have been identified: higher pre-operative TR severity, higher pulmonary artery pressures, mitral replacement rather than repair, worse left ventricular dysfunction and presence of pacemaker leads through the valve area (43). Tricuspid valve morphology may also predict recurrence; tenting height, tenting area (43) and tenting volume (44) are predictors of residual TR following annuloplasty. The current guidelines use a 2D echocardiographic annular measurement to guide intervention (6, 9). In keeping with new recommendations for right-heart imaging that call for three different apical views (45), the reproducibility of this measurement will likely be low and the cut-off for severe dilatation may change (46). Advanced imaging techniques to describe the tricuspid valve apparatus, such as multi-slice computed tomography (47) or 3D echocardiography (48), may have greater utility and should be studied. In addition, we currently lack an understanding of the relative contributions of annular dilatation, RV size/function and pulmonary artery pressures on severity of disease, as well as recurrence following intervention and outcomes. Lee et al. (5) looked at the outcome in 813 patients with severe, unrepaired TR and found the 5-year survival was 74% and the predictors of mortality included absolute TR jet area (a surrogate for TR severity), RV function and pulmonary hypertension. How these factors affect outcomes and recurrence of disease will help determine the appropriate patient population for clinical trials of transcatheter devices.

Can early intervention in the disease process (mild or moderate tricuspid regurgitation) affect outcomes?

In light of the recent evidence showing that untreated TR might be associated with worse prognosis (4, 49) and that progression of TR following isolated left heart valve surgery is highly likely (50, 51) some investigators have suggested that prophylactic treatment of < severe TR is warranted. In fact, guideline recommendations for surgery are currently based upon expert opinion in the absence of evidence-based trial data and support intervening on the tricuspid valve for a dilated tricuspid annulus of ≥40 mm or >21 mm/m², independent of TR severity (6, 9). The target population for prophylactic repair may be patients with mild or moderate TR in the setting of annular dilatation, although studies to test this hypothesis are ongoing (52).

What outcomes are the most relevant for this disease process?

Because of the long natural history of the disease, studies on outcomes may need to focus on soft endpoints. This could include re-hospitalizations, functional status, quality of life or other secondary anatomic/hemodynamic parameters that determine outcomes (i.e., RV function and pulmonary artery pressures). Besides an assessment of functional NYHA Class, disease-specific questionnaires such as the MLHFQ (53) may play a significant role in future trial designs. Tests for validity, reliability and responsiveness were very positive for MLHFQ in a recent study of patients undergoing heart valve surgery (54). A MLHFQ score of less than 24 signifies good health, 24–45 moderate health and 45–105 poor health (53, 55). In addition to patient-reported symptoms, tests such as the 6MWT, per the American Thoracic Society Guidelines [2002] (56), have been used to assess quality of life.

Conclusions

Functional TR is associated with increased mortality if untreated, however, current surgical solutions do have their limitations. Transcatheter solutions may be justified, although the disease itself has not been extensively studied and the interaction between annular dilatation, right heart disease and pulmonary hypertension is poorly understood. A number of questions remain in relation to our poor understanding, which may affect the design of clinical trials for this disease.

Acknowledgements

None.

Footnote

Conflicts of Interest: RT Hahn has received speaker honoraria from Edwards Lifesciences, St. Jude Medical and Boston Scientific; and research grant from Philips Healthcare.

References

1. Cohen SR, Sell JE, McIntosh CL, et al. Tricuspid regurgitation in patients with acquired, chronic, pure...


54. Holmes C, Briffa N. Patient-Reported Outcome Measures (PROMS) in patients undergoing heart valve surgery: why should we measure them and which instruments should we use? Open Heart 2016;3:e000315.


Cite this article as: Hahn RT. Current transcatheter devices to treat functional tricuspid regurgitation with discussion of issues relevant to clinical trial design. Ann Cardiothorac Surg 2017;6(3):240-247. doi: 10.21037/acs.2017.03.10